Anu Gupta

Anu Gupta has a wealth of experience in the pharmaceutical industry. Anu began their career in 1992 as a Senior Demonstrator and Senior Research Associate at the Postgraduate Institute of Medical Education and Research. In 1998, they moved to the California Pacific Medical Center Research Institute as a Post Doctoral fellow. Anu then moved to Stanford University in 2000 as a Post-Doctoral fellow. In 2002, they joined BEXEL Pharmaceuticals, Inc. as a Scientist (Drug Discovery). In 2004, they joined Cleveland Clinic and Case Western Reserve University as a Research Associate, where they identified autophagy as a key resistance mechanism in Glucocorticoid treated lymphoma and CML. In 2007, they moved to Cleveland Clinic as a Research Scientist, where they demonstrated that autophagy is the key mechanism for drug resistance in GIST, and identified several combination partners to inhibit autophagy and induce apoptosis in drug-resistant GIST. In 2015, they joined Deciphera Pharmaceuticals as a Principal Investigator, where they were the project lead in design, execution and analysis of crucial experiments for GIST program, and identified combination partners for ULK1 program. In 2019, they joined Black Diamond Therapeutics as an Associate Director. Currently, they are the Director at Genosco.

Anu Gupta obtained their Doctor of Philosophy (Ph.D.) from JNU in New Delhi from 1987 to 1993. Prior to that, they earned their Master of Science (M.Sc.) in Zoology/Animal Biology from Guru Nanak Dev University from 1984 to 1986. In 2015, they also obtained a certification in Linux networking from IIT-tech institute in Strongsville, OH.